Court Report - June 2014

Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Cephalon Inc. v. Breckenridge Pharmaceutical Inc. et al.
1:14-cv-00671; filed May 27, 2014 in the District Court of Delaware

• Plaintiff:  Cephalon Inc.
• Defendants:  Breckenridge Pharmaceutical Inc.; Natco Pharma Ltd.

Infringement of U.S. Patent Nos. 8,445,524 ("Solid Forms of Bendamustine Hydrochloride," issued May 21, 2013), 8,436,190 ("Bendamustine Pharmaceutical Compositions," issued May 7, 2013), and 8,609,863 ("Bendamustine Pharmaceutical Compositions," issued December 17, 2013) following a Paragraph IV certification as part of Breckenridge's filing of an ANDA to manufacture a generic version of Cephalon's Treanda® (bendamustine hydrochloride, used to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma).  View the complaint here.

AstraZeneca AB v. Aurobindo Pharma Ltd. et al.
1:14-cv-00664; filed May 23, 2014 in the District Court of Delaware

• Plaintiff:  AstraZeneca AB
• Defendants:  Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.

AstraZeneca AB v. Glenmark Generics Ltd. et al.
1:14-cv-00665; filed May 23, 2014 in the District Court of Delaware

• Plaintiff:  AstraZeneca AB
• Defendants:  Glenmark Generics Ltd.; Glenmark Generics Inc. USA

AstraZeneca AB v. Watson Laboratories Inc., et al.
1:14-cv-00666; filed May 23, 2014 in the District Court of Delaware

• Plaintiff:  AstraZeneca AB
• Defendants:  Watson Laboratories Inc.; Actavis Inc.; Actavis LLC

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 7,951,400 ("Coated Tablet Formulation and Method," issued May 31, 2011) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of AstraZeneca's Onglyza® (saxagliptin hydrochloride, used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus).  View the Aurobindo complaint here.

AstraZeneca AB v. Wockhardt Bio AG et al.
1:14-cv-00667; filed May 23, 2014 in the District Court of Delaware

• Plaintiff:  AstraZeneca AB
• Defendants:  Wockhardt Bio AG; Wockhardt USA LLC

Infringement of U.S. Patent Nos. RE44,186 ("Cyclopropyl-Fused Pyrrolidine-Based Inhibitors of Dipeptidyl Peptidase IV and Method," issued April 30, 2013) and 7,951,400 ("Coated Tablet Formulation and Method," issued May 31, 2011) following a Paragraph IV certification as part of Wockhardt's filing of an ANDA to manufacture a generic version of AstraZeneca's Onglyza® (saxagliptin hydrochloride, used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus).  View the complaint here.

 

 


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

more+
less-

McDonnell Boehnen Hulbert & Berghoff LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×